|
David J. Reich, MD, FACS
Chief, Multiorgan Transplantation and Hepatobiliary Surgery; Professor and Vice Chair of Surgery
Drexel University College of Medicine
Phone: 215.762.7143
Email:
djr56@drexel.edu
|
Bio
David J. Reich, MD, FACS, specializes in complex liver surgery, treatments for liver tumors, transplant for high-risk patients, safe use of extended criteria donor organs, and long-term health care following transplantation. He is certified by the American Board of Surgery and is a fellow of the American College of Surgeons.
Dr. Reich was the American Liver Foundation Delaware Valley Chapter "Transplant Surgeon of the Year" honoree in 2004. He is a Castle Connolly and Philadelphia magazine "Top Doc," featured annually from 2010 to 2018.
After receiving his BA from Columbia College of Columbia University and his MD from McGill University, Dr. Reich completed his surgical residency at Beth Israel Medical Center and completed his American Society of Transplant Surgeons–approved multiorgan transplant and hepatobiliary surgery fellowship at the renowned Mount Sinai Hospital Recanati/Miller Transplant Institute in New York City. He has practiced surgery in Philadelphia since 1996.David J. Reich, MD, FACS, is chief of the Division of Multiorgan Transplantation and Hepatobiliary Surgery, and professor and vice chair of the Department of Surgery at Drexel University College of Medicine. He is an internationally recognized leader in organ transplantation and hepatobiliary surgery, with expertise as a clinician, administrator, educator and scientist. He specializes in abdominal organ transplantation and in complex liver surgery.
He has published extensively and lectured internationally regarding research initiatives and clinical aspects of surgery, including pioneering work with donation after cardiac death organ transplantation. Dr. Reich is investigating innovative technologies for artificial liver support and organ preservation, including cellular therapy to augment resuscitative effects of machine perfusion of donor organs.
Dr. Reich is an authority on a wide spectrum of health care governance and practice, including quality improvement, practice standards, policy development, value-based care, health care economics, access to health care, reimbursement, strategic planning, service line development, budgeting, information technology, leadership development, change management, system integration, legislative and regulatory advocacy, and medical education and training across a variety of settings.
Dr. Reich serves in a variety of national leadership positions. He is currently the elected treasurer of the Organ Procurement and Transplantation Network and the United Network for Organ Sharing (OPTN/UNOS) board of directors; OPTN/UNOS manages the U.S. organ transplant network by contract with the federal government. He is one of the six officers of OPTN/UNOS, chairs the Finance Committee, and serves on the Executive and Corporate Affairs Committees. He is a past chair of the OPTN/UNOS Information Technology Advisory Committee, immediate past councilor for Region 2, and past member of the Membership and Professional Standards Committee and the Liver and Intestinal Organ Transplantation Committee. Dr. Reich chairs the Quality and Pay Reform MACRA Task Force of the American Society of Transplant Surgeons (ASTS). He is a past chair of the ASTS Legislative Committee and the Standards on Organ Transplantation Committee, and past member of the Fellowship Training and Workforce Committees. Dr. Reich is a past chair of the Liver Surgery and Transplantation Committee of the American Association for the Study of Liver Diseases, and past member of the Steering, Education Oversight and Scientific Program Committees. He served on the Editorial Board of Liver Transplantation and is an associate editor for Clinical Transplantation.
Education
- BA, Columbia College, Columbia University, 1985
- MD, McGill University, 1989
Research Interests
Organ donation, donation after cardiac death, organ donor pool expansion, machine perfusion of donor organs, artificial liver support, transplantation, immunosuppression trials, hepatocellular carcinoma treatments, health care quality improvement, access to healthcare, healthcare economics, medical education and training.